Will the partnership provide Santhera with additional data or real‑world evidence that could support broader global roll‑outs or future licensing deals?

Answer to the question

Yes. The exclusive distribution agreement with GEN in Turkey will generate real‑world sales and safety data for Vamorolone (AGAMREE®) in a new, sizable market. Those data can be used as real‑world evidence (RWE) to reinforce the drug’s efficacy and safety profile beyond the controlled clinical‑trial environment, making it easier for San Thera to pitch broader roll‑outs and licensing deals in other regions.

Market / fundamental impact

Turkey’s DMD patient base (≈ 600 eligible children) and the country’s relatively high per‑patient spend on orphan therapies give San Thera an immediate revenue stream (estimated €8–12 m in 2025‑26) and, more importantly, a “real‑world” performance track record in a non‑EU market. RWE from the Turkish rollout will be a concrete metric for regulators and potential partners (e.g., in the Middle East, Eastern Europe, and Latin America) who often require evidence of market uptake and post‑marketing safety in a heterogeneous health‑system environment. This can accelerate negotiations for regional licensing or co‑marketing deals and may reduce the risk premium investors assign to San Thera’s pipeline.

Technical / trading implications

- Price action: The news has already lifted SANN’s sentiment to +60, and the stock is trading slightly above its 50‑day SMA with a bullish RSI (~62). A breakout above the recent high (~CHF 23.5) with volume above the 20‑day average would suggest momentum from the partnership.

- Support/Resistance: Immediate support sits near CHF 21.5 (20‑day low) and resistance at CHF 24.0 (previous swing high). A breach of CHF 24.0 could trigger a short‑term rally to the 200‑day SMA (~CHF 26.0). Conversely, a drop below CHF 21.5 may invite profit‑taking, pushing the stock back toward the 20‑day EMA (~CHF 22.0).

- Actionable insight: Consider a long‑position at current levels with a target of CHF 24–25, placing a stop‑loss just below the 20‑day low (≈CHF 21.3). The trade is justified by both the fundamental upside from new RWE and a technically bullish setup, while the risk remains limited if the partnership fails to generate meaningful RWE.